These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion. Xue S; Han Y; Wu F; Wang Q Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025 [TBL] [Abstract][Full Text] [Related]
6. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620 [TBL] [Abstract][Full Text] [Related]
8. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Focosi D; Maggi F Rev Med Virol; 2021 Nov; 31(6):e2231. PubMed ID: 33724631 [TBL] [Abstract][Full Text] [Related]
9. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284 [TBL] [Abstract][Full Text] [Related]
10. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933 [TBL] [Abstract][Full Text] [Related]
11. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Wang R; Zhang Q; Ge J; Ren W; Zhang R; Lan J; Ju B; Su B; Yu F; Chen P; Liao H; Feng Y; Li X; Shi X; Zhang Z; Zhang F; Ding Q; Zhang T; Wang X; Zhang L Immunity; 2021 Jul; 54(7):1611-1621.e5. PubMed ID: 34166623 [TBL] [Abstract][Full Text] [Related]
12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
13. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925 [TBL] [Abstract][Full Text] [Related]
14. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Kim YJ; Jang US; Soh SM; Lee JY; Lee HR Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138 [TBL] [Abstract][Full Text] [Related]
15. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
16. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Villoutreix BO; Calvez V; Marcelin AG; Khatib AM Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580 [TBL] [Abstract][Full Text] [Related]
17. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448 [TBL] [Abstract][Full Text] [Related]
18. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Wu J; Zhang L; Zhang Y; Wang H; Ding R; Nie J; Li Q; Liu S; Yu Y; Yang X; Duan K; Qu X; Wang Y; Huang W Front Immunol; 2021; 12():687869. PubMed ID: 34220844 [TBL] [Abstract][Full Text] [Related]